1-7 of 7
Mars B. van t’ Veer
Close
Sort by
Journal Articles

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

Clinical Trials & Observations
Christian H. Geisler, Mars B. van t’ Veer, Jesper Jurlander, Jan Walewski, Geir Tjønnfjord, Maija Itälä Remes, Eva Kimby, Tomas Kozak, Aaron Polliack, Ka Lung Wu, Shulamiet Wittebol, Martine C. J. Abrahamse-Testroote, Jeanette Doorduijn, Wendimagegn Ghidey Alemayehu, Marinus H. J. van Oers
Journal: Blood
Blood (2014) 123 (21): 3255–3262.
https://doi.org/10.1182/blood-2014-01-547737
Published: 2014
Includes: Supplemental data
Journal Articles

Malignant mesothelioma after radiation treatment for Hodgkin lymphoma

Brief Report
Marie L. De Bruin, Jacobus A. Burgers, Paul Baas, Mars B. van 't Veer, Evert M. Noordijk, Marieke W. J. Louwman, Josée M. Zijlstra, Hendrik van den Berg, Berthe M. P. Aleman, Flora E. van Leeuwen
Journal: Blood
Blood (2009) 113 (16): 3679–3681.
https://doi.org/10.1182/blood-2008-10-184705
Published: 2009
Journal Articles

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Jan J. Cornelissen, Bronno van der Holt, Gregor E. G. Verhoef, Mars B. van 't Veer, Marinus H. J. van Oers, Harry C. Schouten, Gert Ossenkoppele, Pieter Sonneveld, Johan Maertens, Marinus van Marwijk Kooy, Martijn R. Schaafsma, Pierre W. Wijermans, Douwe H. Biesma, Shulamit Wittebol, Paul J. Voogt, Joke W. Baars, Pierre Zachée, Leo F. Verdonck, Bob Löwenberg, Adriaan W. Dekker
Journal: Blood
Blood (2009) 113 (6): 1375–1382.
https://doi.org/10.1182/blood-2008-07-168625
Published: 2009
Includes: Supplemental data
Journal Articles

European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel.

Gina Zini, MD, Barbara Bain, MD, Gianluigi Castoldi, MD, José Cortez, PhD, Judit Csomor, MD, Edgar Faber, MD, Aristoteles Giagounidis, Torsten Haferlach, Petra Kacirkova, MD, Krzysztof Lewandowski, MD, Vincenzo Liso, Estella Matutes, MD, PhD, Marc Maynadie, MD, PhD, John Meletis, MD., Anna Porwit, M. Leticia Ribeiro, MD, Lydia Sreter, MD., Andre Tichelli, Teresa Vallespì, MD.PhD., Mars B. van ‘t Veer, MD, Soledad Woessner, MD, Marie-Christine Bene
Journal: Blood
Blood (2008) 112 (11): 1645.
https://doi.org/10.1182/blood.V112.11.1645.1645
Published: 2008
Journal Articles

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Clinical Trials & Observations
Edo Vellenga, Wim L. J. van Putten, Mars B. van 't Veer, Josée M. Zijlstra, Willem E. Fibbe, Marinus H. J. van Oers, Leo F. Verdonck, Pierre W. Wijermans, Gustaaf W. van Imhoff, Pieternella J. Lugtenburg, Peter C. Huijgens
Journal: Blood
Blood (2008) 111 (2): 537–543.
https://doi.org/10.1182/blood-2007-08-108415
Published: 2008
Includes: Supplemental data
Journal Articles

Late cardiotoxicity after treatment for Hodgkin lymphoma

Clinical Trials & Observations
Berthe M. P. Aleman, Alexandra W. van den Belt-Dusebout, Marie L. De Bruin, Mars B. van 't Veer, Margreet H. A. Baaijens, Jan Paul de Boer, Augustinus A. M. Hart, Willem J. Klokman, Marianne A. Kuenen, Gabey M. Ouwens, Harry Bartelink, Flora E. van Leeuwen
Journal: Blood
Blood (2006) 109 (5): 1878–1886.
https://doi.org/10.1182/blood-2006-07-034405
Published: 2006
Journal Articles

Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH − subgroup of multiple myeloma

Tomasz Szczepański, Mars B. van 't Veer, Ingrid L. M. Wolvers-Tettero, Anton W. Langerak, Jacques J. M. van Dongen
Journal: Blood
Blood (2000) 96 (3): 1087–1093.
https://doi.org/10.1182/blood.V96.3.1087
Published: 2000